Concepedia

Philip R. Dormitzer

PR

85

Publications

35K

Citations

53

H-Index

1989

Active since

Affiliations

Pfizer (United States)(Current)

Novartis (United States)

The University of Texas Medical Branch at Galveston

BioNTech (Germany)

Boston Children's Hospital

Philip R. Dormitzer is an author at Pfizer (United States) specializing in medicine, immunology, and virology.

ORCID

Top concepts

Publications per year

1989–2024

85

Publications

85

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin et al. · New England Journal of Medicine · 2020 · 15.1K citations · Full text

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh, Robert W. Frenck, Ann R. Falsey et al. · New England Journal of Medicine · 2020 · 2.7K citations · Full text

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Uğur Şahin, Alexander Muik, Evelyna Derhovanessian et al. · Nature · 2020 · 2K citations · Full text

, , +7

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin et al. · Nature · 2020 · 1.6K citations · Full text

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Robert W. Frenck, Nicola P. Klein, Nicholas Kitchin et al. · New England Journal of Medicine · 2021 · 913 citations · Full text

Rows per page

1–5 of 85